Showing results (11-20 of 17) with videos related to
Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 17 results.
Pharmaceutics|January 26, 2024
Toxicity Evaluation and Controlled-Release of Curcumin-Loaded Amphiphilic Poly-N-vinylpyrrolidone Nanoparticles: In Vitro and In Vivo ModelsAnna L Luss, Dmitry V Bagrov, Anne V Yagolovich, et al.ACS Applied Bio Materials|November 24, 2025
Codelivery of Bortezomib and Modified DR5-Selective TRAIL via Amphiphilic Poly(N-vinylpyrrolidone) Bionanocomposites to Overcome Glioblastoma ResistanceEkaterina V Kukovyakina, Pavel P Kulikov, Dmitry V Bagrov, et al.International Journal of Biological Macromolecules|November 16, 2023
Dual targeting of DR5 and VEGFR2 molecular pathways by multivalent fusion protein significantly suppresses tumor growth and angiogenesisAlina A Isakova, Artem A Artykov, Ekaterina A Plotnikova, et al.Biomedical Reports|February 12, 2024
Assessment of the effects of amphiphilic poly (N‑vinylpyrrolidone) nanoparticles loaded with bortezomib on glioblastoma cell lines and zebrafish embryosAnne V Yagolovich, Andrey N Kuskov, Pavel P Kulikov, et al.International Journal of Molecular Sciences|May 25, 2024
Correction: Yagolovich et al. DR5-Selective TRAIL Variant DR5-B Functionalized with Tumor-Penetrating iRGD Peptide for Enhanced Antitumor Activity against Glioblastoma. Int. J. Mol. Sci. 2022, 23, 12687Anne V Yagolovich, Alina A Isakova, Artem A Artykov, et al.International Journal of Molecular Sciences|October 27, 2022
DR5-Selective TRAIL Variant DR5-B Functionalized with Tumor-Penetrating iRGD Peptide for Enhanced Antitumor Activity against GlioblastomaAnne V Yagolovich, Alina A Isakova, Artem A Artykov, et al.Journal of Translational Medicine|August 22, 2025
Multivalent fusion protein targeting VEGFR2 and DR5 receptors: assessing the antiangiogenic and antitumor effects via multimodal microangiographyIrina N Druzhkova, Anna G Orlova, Anastasiia S Fedulova, et al.Pageof 2